Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 1, 2012, under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 450,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,448 pence per share; lowest price paid was 1,430 pence per share.
- Treasury Holdings (Settled): 499,865,427 shares (9.18% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,065,427 shares (10.17% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,944,419,217 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 450,000 shares on October 1, 2012. Consequently, the percentage of shares held in Treasury increased to 10.17% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,944,419,217) for calculating disclosure thresholds under the Financial Services Authority's rules.
- Confirm the impact of the 10.17% treasury holding on total voting rights.
- Note that the filing does not contain financial performance data for the period.